15 completed, 3 recruiting, 1 active not recruiting, 1 terminated. 6 Phase 3, 5 Phase 4, 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 3, Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 4 | 5 | Completed 3, Recruiting 2 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Vitamin K antagonist: new trials by email Literature Review of Vitamin K antagonist trials Research Report on Vitamin K antagonist
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimizing Anticoagulation in Pregnancies With Mechanical Heart Valves LMWH and LDA, Vitamin K antagonists (e.g warfarin)+/- LDA, Sequential therapy +/- LDA - Pregnancy, Prosthetic Heart Valve | Not applicable | Recruiting | Mount Sinai Hospital, Canada | 100 | 2026-05-26 | 2026-06-22 |
| Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease Rivaroxaban Oral Tablet [Xarelto], Aspirin or Clopidogrel, Warfarin - Kawasaki Disease, Coronary Artery Aneurysm | Phase 4 | Recruiting | Children's Hospital of Fudan University | 100 | 2025-06-01 | 2026-07-06 |
| Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device Aspirin, Warfarin - Bleeding, Clot Blood | Phase 4 | Recruiting | Columbia University | 128 | 2024-10-02 | 2026-02-27 |
| Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus Vitamin K antagonist, Direct oral anticoagulant - Intracardiac Thrombus, STEMI | Phase 3 | Active not recruiting | Centre Hospitalier Universitaire de Nīmes | 340 | 2023-05-15 | 2026-02-17 |
| Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events Rivaroxaban 20 MG [Xarelto], Aspirin 300mg, Acenocoumarol Oral Tablet - Venous Thromboembolism, Anticoagulant-induced Bleeding | Phase 2 / Phase 3 | Completed | Instituto Mexicano del Seguro Social | 58 | 2021-01-03 | 2022-08-25 |
| Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant Rivaroxaban, Vitamin K Antagonist - ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus | Phase 3 | Unknown | RenJi Hospital | 280 | 2020-02-01 | 2023-06-01 |
| Registration of Idarucizumab for Patients with IntraCranial Hemorrhage Dabigatran Etexilate Oral Capsule [Pradaxa], Idarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND], Vitamin K antagonist - Intracranial Hemorrhage | Completed | University Hospital, Essen | 104 | 2019-09-19 | 2024-12-09 | |
| Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice Rivaroxaban (Xarelto, BAY59-7939), Apixaban (Eliquis), Warfarin - Atrial Fibrillation | Completed | Bayer | 45164 | 2019-02-28 | 2021-10-28 | |
| Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis Rivaroxaban 15 mg, Warfarin - Prostheses and Implants, Stroke | Phase 2 / Phase 3 | Terminated | Hospital Geral Roberto Santos | 50 | 2018-07-10 | 2020-05-15 |
| The Greek AntiPlatElet Atrial Fibrillation Registry. VKA, NOAC - Atrial Fibrillation, Coronary Artery Disease | Completed | Attikon Hospital | 654 | 2017-12-01 | 2021-07-26 | |
| Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Edoxaban, Clopidogrel, Prasugrel - Atrial Fibrillation | Phase 3 | Completed | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 1506 | 2017-02-24 | 2020-05-06 |
| Patient Convenience Study- NIS RELATE Pradaxa (dabigatran), Vitamin K antagonist - Atrial Fibrillation | Completed | Boehringer Ingelheim | 1313 | 2016-06-20 | 2019-07-08 | |
| Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist Apixaban, Vitamin K antagonist - Atrial Fibrillation | Completed | Bayer | 18591 | 2016-02-12 | 2017-04-05 | |
| Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist Dabigatran (Pradaxa), Vitamin K antagonist - Atrial Fibrillation | Completed | Bayer | 56039 | 2016-02-12 | 2017-04-05 | |
| Subtherapeutic INR Levels in Patients With AVK: Incidence, Associated Factors, Prognosis and Control Strategies Vitamin K Antagonist - Atrial Fibrillation | Completed | Bayer | 1013 | 2015-10-01 | 2019-04-25 | |
| A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart Apixaban, vitamin K antagonist, Acetylsalicylic acid - Acute Coronary Syndromes | Phase 4 | Completed | Bristol-Myers Squibb | 4614 | 2015-06-04 | 2020-06-11 |
| Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over Direct oral antocoagulant: dabigatran, rivaroxaban, apixaban, Vitamin K antagonist: warfarin, fluindione, acenocoumarol - Atrial Fibrillation | Completed | Assistance Publique - Hôpitaux de Paris | 159 | 2015-02-01 | 2022-03-29 | |
| Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy Vitamin K antagonist, Apixaban - Atrial Fibrillation | Phase 4 | Completed | Atrial Fibrillation Network | 676 | 2014-12-01 | 2017-10-20 |
| APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study VKA, Apixaban, dabigatran - Anticoagulation | Completed | Bristol-Myers Squibb | 321501 | 2014-01-01 | 2022-05-18 | |
| Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD Acetylsalicylic acid, Vitamin K antagonist - Cervical Artery Dissection | Phase 3 | Completed | Stefan Engelter | 194 | 2013-09-01 | 2024-05-21 |
Showing 20 of 21. Sign in to see all of them.
Atrial Fibrillation (9) · Stroke (5) · Acute Coronary Syndrome (2) · Pulmonary Embolism (2) · ST Elevation Myocardial Infarction (2) · Coronary Aneurysm (1) · Coronary Artery Disease (1) · Embolism (1) · Heart Failure (1) · Heart Valve Diseases (1) · Hemorrhage (1) · Hemostatic Disorders (1) · Intracranial Hemorrhages (1) · Ischemic Attack, Transient (1) · Mucocutaneous Lymph Node Syndrome (1)
Bayer (4) · Bristol-Myers Squibb (2) · Assistance Publique - Hôpitaux de Paris (1) · Atrial Fibrillation Network (1) · Attikon Hospital (1) · Boehringer Ingelheim (1) · Centre Hospitalier Universitaire de Nīmes (1) · Children's Hospital of Fudan University (1) · Columbia University (1) · Complejo Hospitalario Xeral-Calde (1) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (1) · Hospital Geral Roberto Santos (1) · Instituto Mexicano del Seguro Social (1) · Mount Sinai Hospital, Canada (1) · RenJi Hospital (1)
France (5) · Germany (5) · Spain (5) · United States (5) · United Kingdom (4) · Austria (3) · Belgium (3) · Denmark (3) · Italy (3) · Netherlands (3) · South Korea (3) · Switzerland (3) · Brazil (2) · Canada (2) · China (2)
Alejandro Veres Racamonde, MD (1) · Andre Duraes, PhD (1) · Andreas Gotte, Prof., MD (1) · Dimitrios Alexopoulos, MD (1) · Fang Liu, MD (1) · Florence Tubach, PhD (1) · Hans Diener, Prof. Dr. (1) · Nir Uriel, MD (1) · Pascal Vranckx, MD (1)
PMID 29421002, PMID 29898844, PMID 30293126, PMID 30883055, PMID 31492505, PMID 31557056, PMID 31707833, PMID 32223444, PMID 32355836, PMID 32725107, PMID 33034806, PMID 33098470, PMID 33150497, PMID 33461308, PMID 34857666, PMID 35115097, PMID 35135308, PMID 35172988, PMID 35612866, PMID 36410034, PMID 37897713, PMID 38876331, PMID 39197976, PMID 39502066, PMID 39557109, PMID 39910883, PMID 39918467, PMID 40117694
2014 (2), 2016 (1)